Skip to main content Skip to section navigation Skip to footer
Lexaria Bioscience Corp.Lexaria BioscienceLexaria Bioscience
Lexaria Bioscience Corp.

NASDAQ:LEXX; NASDAQ WARRANT:LEXXW

  • Home
  • About
    • Management
    • Board of Directors
    • Advisors & Consultants
  • Technology
    • Overview
    • Commercial Applications
    • Research
    • Patent Portfolio
  • Licensing Opportunities
  • Investors
Contact

Press Releases

Investors

Investors

  • Overview
  • News & Events
    • Overview
    • Press Releases
    • IR Calendar
    • Email Alerts
  • Presentations
  • Company Info
    • Overview
    • Management Team
    • Contacts
    • 2023 Annual General Meeting
    • 2023 Special Meeting
    • FAQ
  • Analyst Coverage
  • Financial Info
    • Overview
    • Financial Results
    • Income Statement
    • Balance Sheet
    • Cash Flow
  • Stock Data
    • Quote
    • Charts
    • Historical Data
  • SEC Filings
    • Overview
    • All SEC Filings
    • Annual Reports
    • Quarterly Reports
    • Section 16 Filings
  • SEDAR+
  • Legend Removal
  • Governance
    • Overview
    • Board of Directors
    • Board Committees
    • Governance Documents
  • News & Events

  • Overview
  • Press Releases
  • IR Calendar
  • Email Alerts
Jun 12, 2023 9:20am EDT

Lexaria Appoints New Chief Financial Officer

May 23, 2023 9:05am EDT

Lexaria Discovers that DehydraTECH-CBD Treatment in Hypertension Study HYPER-H21-4 Resulted in Reduction in Pro-Inflammatory Biomarkers

May 18, 2023 9:05am EDT

Lexaria's Hormone Study Shows Significant Enhancement in Oral Estradiol Delivery

May 11, 2023 1:45pm EDT

Lexaria Bioscience Announces Closing of $2.0 Million Public Offering

May 11, 2023 9:00am EDT

cGMP Manufacturing Complete for Lexaria's Upcoming U.S. Phase 1b Hypertension Clinical Trial

May 10, 2023 10:15am EDT

Lexaria Announces 2023 Annual Meeting Results

May 08, 2023 8:35pm EDT

Lexaria Bioscience Announces Pricing of $2.0 Million Public Offering

May 08, 2023 9:05am EDT

Lexaria’s Human Clinical Nicotine Study Completes Dosing as Planned

Apr 24, 2023 9:00am EDT

Lexaria Awards CRO Contract for Upcoming U.S. Phase 1b Hypertension Study

Apr 20, 2023 9:00am EDT

Lexaria is Receiving Four New Patents

  • Previous Pagearrow_back
  • Page 1
  • Page 2
  • Page 3
  • Page 4
  • Page 5
  • Page 6
  • Page 7
  • Page 8
  • Page 9
  • Page 10
  • …
  • Page 22
  • Next Pagearrow_forward
rss_feed News RSS
  • Email Alerts
  • Contacts
  • RSS News Feed
Lexaria Bioscience Corp. (NASDAQ:LEXX) has developed and out-licenses its disruptive and cost-effective DehydraTECH™ technology that promotes healthier administration methods, lower overall dosing and higher effectiveness of ingestible drugs and other beneficial molecules.

250.765.6424
info@lexariabioscience.com

Canadian Operations
#100-740 McCurdy Road
Kelowna, BC, V1X2P7

US Operations
2226 W. Northern Avenue
Phoenix, AZ 85021

Privacy Policy

General Disclaimer:
No statement in this web site has been evaluated by the Food and Drug Administration (FDA). Furthermore, none of the statements in this web site should be construed as dispensing medical advice or making claims regarding the cure of diseases…

Read More

Copyright ©2023 All rights reserved.

Back to the top